Evaluation of peripheral lymphocyte subsets in acne vulgaris patients before and after systemic isotretinoin treatment
Sibel Dogan Gunaydin1, Ilhan Tezcan2
1 Department of Dermatology and Venereology, Hacettepe University, Ankara, Turkey
2 Department of Child Health and Diseases, Division of Pediatric Immunology, School of Medicine, Hacettepe University, Ankara, Turkey
OBJECTIVES: Isotretinoin (ISO) is a retinoic acid-derived molecule which is very efficient in the treatment of acne vulgaris (AV). Little is known regarding alterating affects of systemic ISO on immune system.
SUBJECTS AND METHODS: Thirty-two patients with moderate and severe AV with indications for systemic ISO treatment were recruited. The evaluation of peripheral blood lymphocyte subsets was made on treatment initiation and at the end of the therapy by flow cytometry.
RESULTS: CD16/56+ natural killer (NK) cell levels were higher in patients with severe acne compared to moderate acne (P = 0.009). CD45RA+ (naive) cell levels decreased significantly after systemic ISO treatment; the mean percentage was 66.9 ± 6.5 which decreased to 63.9 ± 7.5 after treatment (P = 0.013). CD19+ cell levels were also significantly increased; mean percentage (%) and absolute cell counts were 8.0 ± 3.1 and 161.3 ± 7.36 cells/μl which increased to 10 ± 2.7 and 227.7 ± 108.7 cells/μl, at the end of treatment, respectively (P = 0.007, P = 0.011).
CONCLUSIONS: NK cell count may be a parameter related to acne severity. Systemic ISO may have an inhibitory effect on naïve T cells. Finally, systemic ISO seems to stimulate mature B-cell proliferation.
Sibel Dogan Gunaydin
No. 9 Nolu Kapi 2. Kat Hacettepe, Eriskin Hastanesi, Sihhiye 06100, Ankara
|How to cite this article:|
Gunaydin SD, Tezcan I. Evaluation of peripheral lymphocyte subsets in acne vulgaris patients before and after systemic isotretinoin treatment.Indian J Pharmacol 2022;54:338-344
|How to cite this URL:|
Gunaydin SD, Tezcan I. Evaluation of peripheral lymphocyte subsets in acne vulgaris patients before and after systemic isotretinoin treatment. Indian J Pharmacol [serial online] 2022 [cited 2023 Mar 21 ];54:338-344
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2022;volume=54;issue=5;spage=338;epage=344;aulast=Gunaydin;type=0